Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.5% – What’s Next?

Xilio Therapeutics, Inc. (NASDAQ:XLO) shares traded down 0.5% during trading on Friday . The stock traded as low as $0.6550 and last traded at $0.6619. 218,489 shares changed hands during trading, a decline of 57% from the average session volume of 504,235 shares. The stock had previously closed at $0.6653.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Xilio Therapeutics in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $2.00.

Xilio Therapeutics Trading Down 0.5%

The firm’s 50-day moving average price is $0.74 and its 200 day moving average price is $0.73. The company has a market capitalization of $34.75 million, a price-to-earnings ratio of -1.02 and a beta of -0.07.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). Xilio Therapeutics had a negative net margin of 183.90% and a negative return on equity of 679.66%. The business had revenue of $19.07 million for the quarter, compared to analyst estimates of $18.64 million. As a group, equities research analysts anticipate that Xilio Therapeutics, Inc. will post -1.14 earnings per share for the current fiscal year.

Institutional Trading of Xilio Therapeutics

A hedge fund recently raised its stake in Xilio Therapeutics stock. Squarepoint Ops LLC boosted its holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO) by 39.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 328,794 shares of the company’s stock after buying an additional 93,338 shares during the quarter. Squarepoint Ops LLC owned approximately 0.63% of Xilio Therapeutics worth $277,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.